Advertisement
Advertisement
U.S. markets open in 5 hours 15 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Invitae Corporation (NVTA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
5.01-0.36 (-6.70%)
At close: 04:00PM EDT
4.86 -0.15 (-2.99%)
Pre-Market: 04:15AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close5.37
Open5.40
Bid0.00 x 1000
Ask0.00 x 3200
Day's Range4.70 - 6.15
52 Week Range1.83 - 32.93
Volume53,925,831
Avg. Volume18,333,296
Market Cap1.179B
Beta (5Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-2.06
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NVTA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Invitae Corporation
    Analyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
    Rating
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • TheStreet.com

    Invitae Goes Full Meme Stock. What's Next?

    Shares of the genetic testing company have more than doubled in less than a week. It likely isn't durable.

  • Motley Fool

    Invitae Stock Soars 277% in a Day: Time to Buy?

    Even as Invitae increases its margins and reduces cash burn, eager traders still might have gotten ahead of themselves.

  • Motley Fool

    Is Soaring Invitae Stock a Smart Buy Now?

    Shares of Invitae (NYSE: NVTA) recently shot up like a rocket in response to a second-quarter earnings call that was a lot more positive than expected. Bringing comprehensive genetic information into mainstream medicine could make Invitae a top performer in the years ahead. Let's look a little closer at the company's performance this year to see if it's a smart stock to buy now and hold for the long run.

Advertisement
Advertisement